Chronic lymphocytic leukemia (CLL) is characterized by the clonal expansion of CD5-expressing B lymphocytes. Most studies have found that these leukemic CD5 + B cells, like their normal counterparts, use immunoglobulin (Ig) variable (V) region genes that exhibit minimal, if any, somatic diversity. These and other observations have suggested that CD5 § B cells may be incapable of generating Ig V gene diversity, and therefore may not be able to develop higher affinity binding sites that could be selected by antigen. However, most of the studies of CLL and normal CD5 + B cells have focused on IgM-producing cells. Since somatic mutations are most often seen in B cells that have undergone an isotype class switch, we analyzed the Ig heavy (H) and light (L) chain variable region genes of seven IgG + CD5 + CLL B cells to determine if somatic diversification and antigen selection had occurred. The data derived provide evidence for skewed use, somatic diversification, and antigenic selection of the Ig V region genes. Nonrandom use of both H and L chain V region genes was manifested by an overrepresentation of VH4 and V~I family genes and the underrepresentation of the JH4 gene segment. Furthermore, VH4 gene use was restricted to only two family members (4.21 and 4.18). In four of the seven cases, the V. and VL genes displayed />5% difference from the most homologous known germline counterparts. Polymerase chain reaction and Southern blot analyses performed in two of these patients demonstrated that their unique V. CDR2 and adjacent sequences were not present in their germline DNA. In addition, a significant level of diversity was seen in the rearranged DJ8 segments and at the VL-JL junctions of every patient that occurred both at the time of recombination and subsequently. The localization of replacement changes to complementarity determining regions of some patients suggested that antigen selection had occurred. Furthermore, the mutations identified in the V~ and VL genes of each individual patient were strikingly similar, both in number and location. Collectively, the data indicate that a subset of CD5 § CLL B cells can display Ig V region gene mutations. In addition, they are consistent with the notions that in some cases antigen selection of these mutations may have occurred, and that antigen stimulation may be a promoting factor in the evolution of certain CLL clones.
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This work was presented in part at the International Conference on Polyreactive and Monoreactive Antibodies in Natural Immunity and Autoimmune Diseases held at the National Institutes of Health, Bethesda, MD, 23-25 September 1992. most invariably expresses surface membrane CD5 (for a review see reference 1). Over the years, investigators have studied these cells to understand both the normal physiology of this subset of human B cells as well as the abnormal features of the B lymphocytes expanded in this disease. Studies to date suggest that the B cells that are clonally expanded in CLL use a biased set of Ig V genes (for a review see reference 2) to code for low affinity, polyreactive autoantibodies (3) (4) (5) , predominantly of the IgM class. Although numerous studies have noted that these Ig V genes rarely undergo somatic mu-ration (2), this principle was challenged by the study of Cai et al. (6) , which documented V, gene mutations among a cohort of CLL patients whose malignant clone used the V~251 gene. Surprisingly, however, a follow-up study (7) of a larger, well-characterized group of patients whose leukemic cells used the same gene failed to confirm these findings, thus leaving this dilemma unresolved.
It is important to note, however, that most of these studies of CD5 § CLL B cells have dealt with IgM-producing cells. Since antigen stimulation resulting in somatic diversification may occur more often at the time of or among isotypeswitched B cells (8) , CD5 + B cells producing non-IgM antibodies may exhibit different features, both at the protein and nucleic acid levels. To test this hypothesis and to help resolve the issue of the capacity of these cells to somatically diversify their Ig V genes, we have analyzed the Ig V genes used by CD5 + CLL cells that produce IgG antibodies. The data demonstrate an overrepresentation of Ig V. and V~ family genes and an underrepresentation of a frequently employed J. segment. In addition, there is strong evidence that the Ig V gene segments of both the H and L chains from several of these CD5 + CLL clones have undergone somatic mutation. Finally, the location of replacement substitutions suggests that some of these mutations may have been antigen driven and selected.
Materials and Methods

CLL Cells and Heterohybridomas. Seven patients with CLL
whose CD5 § leukemic B cell clones produced IgG were studied. As recently reported (9) , each patient exhibited clinical features typical for CLL, with stages ranging from 0 to IV (Rai classification; 10) . In addition, all exhibited an expanded population of circulating IgG+CD5 + B cells as determined by immunofluorescence, although the percentages of IgG+CD5 + coexpressing cells varied among the various patients (range: 64-92%). Serologic and immunofluorescence studies demonstrated that five of these CLL clones produced IgG1 and two IgG3 (11) .
Heterohybridomas made with these cells were screened for the secretion of Ig H and L chains that corresponded to the original CD5 + CLL B cell, and appropriate lines were cloned by limiting dilution to ensure monoclonality (9) . V gene fingerprinting analyses (11, 12) were performed to confirm that the V. and VL genes used by the heterohybridomas were derived from the CLL clones overexpanded in vivo. All seven hybridomas expressed V, CDR3 lengths identical with those of the CLL cells (9) . More recent studies indicated that six of the hybridomas had identical VL CDR3 lengths. Since the fingerprinting results for hybridoma no. 039 were equivocal, the DNA sequence of this gene was determined from the circulating CLL cells.
Reverse Transc@tase (RT) PCR. The primers for the V, and VL families and C. and ~ amplification were as reported in references 13 and 14, respectively. Total RNA (500 rig) was reverse transcribed by use of avian myeloblastosis virus KT (GIBCO BRL, Gaithersburg, MD) and the appropriate C. or C~ primer, and then specific amplification of the cDNA was accomplished as described (15) .
Cloning and Sequencing of PCR Products. PCR products were
force cloned into the pUC19 vector after digestion with EcoRI and HindlII. Clones were isolated and sequenced in both directions by the Sanger dideoxy chain termination method (16), either manually or by an automated sequenator (model 373A; Applied Biosystems, Inc., Foster City, CA) using the DyeDeoxy TM terminator kit (Applied Biosystems Inc.).
Southern Blot Analyses. Genomic DNA was amplified by PCK with selected primers, electrophoresed through 1% agarose gel, transferred onto nylon membranes (Separation, Inc,. Westboro, MA), and UV cross-linked as described previously (15) . Blots then were hybridized with 32P-labeled probes in hybridization solution (QuikHyb; Stratagene Inc., LaJolla, CA) according to the manufacturer's instructions. When appropriate, stripping was accomplished by incubation at 72~ for 1 h in 2.5 mM Tris-HCl (pH 8.0), 0.1 mM EDTA, and 0.5 mM sodium pyrophosphate. After washing, blots were exposed overnight on photographic film (XAKS; Eastman Kodak Co., Rochester, NY). Biased VH Gene Usage, Only two gene families were used, with five patients' cells using V.4 family genes and two V.3 family genes. Of the 12 or more members of this moderately sized family (18) , only 2 were represented in this group: V.4.21 (n = 3; patients 001, 033, and 055) and V~4.18 (n --2; 039 and 057). Because of the small number of V~3 genes found, no conclusions about gene frequency use can be drawn.
Results
VH Gene Segment Analyses
Different Degrees of Similarity with Germline Genes.
Two of the VH4 CLL samples (patients 039 and 057) exhibit a high degree of homology (>98.5%) with the presumed germline ancestor (Fig. 1) , whereas the other three (001, 033 and 055) display considerably less identity (95, 92, and 91%, respectively). Similarly, one of the V.3 cases (040) is highly homologous with a germline gene (>98.5%), whereas much less similarity (94%) is observed in the other (030). The three V,4 CLL B cdls that show significant differences from their ancestral gene (<95% homology; 001, 033, and 055) all use the V, 4.21 gene. Those patients using the V. 4.18 gene exhibit >98.5% homology to the germline.
Differences in Distribution of Nucleotide Changes. For certain
patients (001 and 033), the differences from the ancestral genes are located throughout the V, segment (Fig. 1) , whereas for others (030 and 055), differences are nonrandomly distributed. In these latter two patients, the differences cluster predominantly within complementarity determining region (CDR)2 for patient 030 and within CDK2 and FR3 for patient 055.
Differences in Deduced Amino Acid Sequences. When the nucleotide differences of the patients are analyzed for their effects on the amino acid sequence of the deduced Ig H chain proteins (Fig. 2 A) , there are striking differences in replacement/silent (R/S) substitution ratios for certain patients. For example, for patient 030, the K/S of CDK 1,2 is 7.0 and that of framework regions (FR) 1,2,3 is 0.6. In contrast, for patient 033, the K/S in CDK 1,2 is 0.8 and in FR 1,2,3 is 1.3. Patient 055 illustrates an overall R/S for CDK 1,2 of 1.7 and for FK 1,2,3 of 1.3, although most of these latter substitutions occur in a defined region of FK3. A   VH&   1  2  3  4  5  6  7  8  9  10  ii  12  13  1  7  18  19  20  21  22  23  24  25  26  29  28  29  30  &.al  CAG G'TG CAG CTA CAG CAG TGG GGC GCA GGA CTG TTG AAG CCT TCG GAG ACC CTG T~C CTC Ace TC.C GCT GTC TAT GGT GGG TCC 'PTC AGT  GGT TAC TAC TQG 
Mutation and Selection of Ig V Genes in IgG § , CD5 § CLL B Cells
Absence of the Patient-specific Sequences in Germline DNA
Next we investigated whether the differences in the V. gene segments observed in patients 030 and 055 were somatically generated. These patients were chosen since their V. sequences were significantly different from the presumed germline counterparts, and these differences clustered within areas of the gene that would likely directly influence the shape of the antigen-binding groove. Southern Blotting Analyses. A second approach involved the probing of unrearranged DNA with radiolabeled oligonucleotides specific for the mutation-specific or conserved se-quences of each patient. In these studies, germline and rearranged DNA were amplified with the same sets of general G primers described above and then exposed to probes complementary to either the unique CDK2 sequence or the conserved FR sequence as a positive control. Fig. 4 indicates the results of these experiments for patient 030. Hybridization with the mutation-specific probes occurred only with the rearranged DNA, whereas hybridization of the conserved probe was seen with both the unrearranged and rearranged DNA. These differences in binding of the mutation-specific probes occurred despite the use of longer incubation times (16 vs. 2 h) and less stringent hybridization buffers and washing regimens (2 vs. 0.1 x SSC; room temperature vs. 40~ than those used for the conserved probes.
PCR Analyses.
D andJ, Gene Segment Analyses
The sequences of the D and JH segments expressed by the CD5 + CLL B cells are listed in G.Rev. 5'GGCATTGTCTCT-GGAGATGG) and transferred onto nylon membranes. Blots were hybridized first with a mutation-specific 32p-labeled probe (5'CAG-TATTAGAACTGATGGGG), and after stripping by incubation at 72~ for 1 h in 2.5 mM Tris-HC1 (pH 8.0), 0.1 mM EDTA, and 0.5 mM sodium pyrophosphate, were hybridized with the conserved sequence probe (5'GTGAAGGGCCGATTCA). For the mutation-specific probe, hybridization was carried out at 42~ overnight; for the conserved sequence probe, hybridization was performed at the same temperature for 2 h. For the conserved sequence probe, blots were washed twice at room temperature for 15 min with 2 x SSC, 0.1% SDS, and then once at 40~ for 30 min with 0.1 x SSC, 0.1% SDS. For the mutation-specific probe, washes were performed under less stringent conditions with 2 x SSC, 0.1% SDS, at room temperature for 15 min. that the V. genes of these patients were two of the most divergent from their germline counterparts (Fig. 1) .
The J, segments also show significant alterations from the germline, with examples of both trimming at the D-J joints and internal deletion (Fig. 5 B) . Furthermore, significant numbers of N additions were identifiable for all patients except 040.
Finally, presumptive nucleotide substitutions were found in the J, and D segments of all patients in whom likely germline progenitor D segments could be identified. Patients 039 and 040 are noteworthy since in both cases the level of VH gene diversification was negligible, whereas the levels of DJ. mutation were considerable.
Deduced Amino Acid Differences in CDR3. The nucleotide changes in the D and J, segments resulted in CDR3 lengths that were quite disparate, ranging from 11 to 23 amino acids (Fig. 2 A) . A dramatic similarity in amino acid sequence was found in the CDR3 of patients 039 and 057. This sequence similarity includes an identical stretch of 6 amino acids that is separated by four mismatches from another identical stretch of 5 amino acids.
Reidentification of CLL-unique Sequences in Freshly Isolated CD5 § CLL B Cells
Since this study spanned 3 yr, attempts were made to determine if new mutations had occurred in vivo over this time frame. Patients 001, 030, 033, 039, and 057 were reanalyzed. Patients 055 and 040 could not be included in this evaluation since the former was treated with fludarabine that essentially eliminated circulating CLL B ceils, and the latter had died.
The unique V gene arrays that had been created by mutation, N addition, and D/J segment substitution and deletion served as unequivocal signatures of the CLL clones.
RNA was obtained from freshly isolated B cells, reverse transcribed, amplified with appropriate patient-specific FR2 upstream primer and the C'y downstream primer, and sequenced. In three patients (001, 033, and 039), the newly defined sequences were identical to those listed in Fig. 1 (data  not shown) . A single-point alteration that was not productive of an amino acid change was found in patient 030. The most significant differences were found in patient 057, in whom three point mutations in CDR 2 and 3 were detected among two clones; one of these (G ~ A) resulted in an amino acid change (Ser ~ Asn) at codon 52 of CDR2. Nonrandom V~ Gene Family Use. Of the six CLL clones expressing r chains, five used a V~I family gene (patients 030, 040, 055, and 057). However, unlike the Ig V.4 gene use, which was restricted to only two individual family members, four different V~I family genes were represented ( Fig. 6 and Table 1 ). I"  CDR 1  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25 -/ + -/ + -* Adapted, in part, from references 9 and 22. * Cross-reactive idiotypic (CRI) determinants detected by solid-phase RIA as described (33, 34) . S Notations preceding the slash (/) relate to the relative numbers of N additions; notations after the slash relate to degrees of trimming at joints.
VL Gene Segment Analyses
Different Degrees of Similarity with Germline V~ Genes That Parallel Those of the Corresponding VH Gene. The V~I genes
II Notations preceding the slash relate to the relative number of mutations in V. or Vt; those after the slash relate to DJ. and Jt segments.
R/S substitution ratios >3 for the CDR and <1 for the FR (Fig. 2 B) . These patterns closely resemble those seen for the corresponding H chain gene in almost every case.
Random Use of JL Gene Segments.
Unlike the nonrandom use of J., JL families are used in an apparently stochastic fashion (Fig. 7) . In every case, there is evidence for trimming of the JL segments as well as examples of a limited number of N additions in patients 039, 040, and 057 (Fig. 7) . The combination of trimming and N addition has resulted in VL-J~ junctional diversity in each case.
Discussion
The preceding data demonstrate that certain CD5 + CLL B cells display skewed use, somatic diversification, and evi-dence consistent with antigenic selection of their Ig H and L chain V region genes. Table 1 collates the genetic data from this study and the serologic data from a companion study (9) to provide a comprehensive view of the characteristics of these cells.
Gene Segment Use. Evidence for nonrandom use of both H and L chain V region genes was manifested as an overrepresentation of V.4 and J~I family genes and underrepresentation of the JH4 gene segment. VH4 gene use was restricted further to only two (4.21 and 4.18) of the 12-16 members of the family (18) . A restriction to specific gene members was not seen for J~I, although the 02 gene was expressed in two patients.
The frequency of V.4 gene use among our patients is TTT GGC CAG GGG ACC AAG CTG GAG ATC AAA C TTC GGC GGA GGG ACC AAG GTG GAG ATC AAA C
Comparison of the nucleotide sequences of the JL gene segments. significantly different from the potential repertoire available in the germline (exact goodness of fit test;/) <0.005; 20) but not from a composite of the available CLL V gene sequences (21) . Nevertheless, the overexpression of the specific V.4 genes 4.21 and 4.18 is striking considering that two prior studies failed to document such a restricted use of individual genes within a V. family in CLL B cells (23, 24) . Furthermore, the absence of J,4 use by our patients' B cells is significantly different not only from healthy adult blood B cells (p <0.003; 19) but also from most CLL patients ~ <0.002; 21). In addition, the overrepresentation of V~I family genes in our patients differs from that of the V~IIIb gene humkv325/A27 reported in other cohorts with CLL (25), although one of our patient's (033) CLL cells did use this gene. Finally, the biased use of Ig genes by our CLL patients extends to C, and involves the restricted use of IgG1 and IgG3 and the absence of IgG2 (9, and Table 1 ). The lack of IgG2 expression is striking since in healthy adults, B cells producing this subclass are of equal frequency to those producing IgG1 (26) . Thus our data support the principle that CD5 + CLL B cells demonstrate biased use of Ig H and L chain gene segments. Those biases observed in our patients that differ from those reported previously may indicate different selective pressures in these IgG-producing CLL ceils compared with most CLL patients that develop a clonal expansion of IgM-bearing B cells (92-95%; 27). These findings favor the concept that the V gene biases in CD5 + B cells can result from antigen selection (28, 29) rather than inherent processes programmed before antigen receptor expression (30).
Somatic Diversification. Some level of somatic diversification was found in every case. These diversification events occurred both at the time of gene segment recombination as well as after the attainment of a competent B cell antigen-receptor complex. For example, at the times of D-J. and V.-DJ. joining and VL-J~ joining, varying levels of N addition and trimming occurred in the H and L chains of most patients. It is noteworthy that the combined effects of trimming and N addition in VL, however, conserved CDR3 lengths of nine amino acids. It is now known that ~20% of normal human B cells exhibit additions of nucleotides at the VL-JL junction that can alter CDR3 length (31), although longer CDR3 lengths appear to be more frequent in patients with inflammatory diseases like rheumatoid arthritis (32).
Multiple somatic changes not related to the recombination process also occurred in regions of these genes. Four patients showed significant variations of their H and L chain V genes from the reported germline counterparts. The level and location of these differences in the H and L chains were quite similar within an individual patient's leukemic clone. The possibility that these differences reflected the presence of heretofore unreported gene segments was ruled out for the two patients studied in detail (030 and 055). Interestingly, a cross-reactive idiotype found almost exclusively on mutated IgG autoantibodies and not within the germline (F4; 33) was expressed by these two IgG molecules as well as that produced by patient 033 (9 and Table 1 ), providing serologic corroboration of the molecular data obtained.
However, mutations were not seen in the V. genes of all patients studied. Specifically the two patients using the V. 4.18 gene demonstrated very minor differences from the germline counterpart. In contrast, the three patients that used the V, 4.21 gene demonstrated significant somatic diversification. This observation confirms those recently reported (21, 35) on the discordant occurrence of mutations in these two gene segments in CLL.
The diversification detected in the IgG-producing B cells of these patients is not restricted to the V. or VL segments. Essentially all of the patients demonstrated differences from the germline D and J, segments, and every patient showed diversity at the VL-J~ junctions. These latter changes are striking since they result in the acquisition of a positively charged arginine residue at the joints in two patients (039 and 057) and the creation of a threonine residue one position downstream from the joints in five patients (030, 033, 040, 055, and 057).
Most previous reports suggest that CD5 + CLL B cells undergo little somatic diversification (2), although certain studies have contained occasional patients whose V genes diverge from the presumed germline counterparts (for review see reference 21). The most striking study of V. gene mutation in CLL is that of Cai et al. (6) , who documented extensive and selected mutations in IgM-producing CLL B cells that used the V.251 gene. This group of patients was somewhat atypical, however, since •30% of the patients studied used this gene segment, a frequency not in line with most other studies. Since neither the frequency of V~251 use nor the presence of extensive mutations could be corroborated by Rassenti and Kipps (7), these investigators suggested that the patients studied by Cai et al. (6) might not be representative of the disease or that subsets of patients' CLL B cells might differ in their ability to develop somatic mutations. In support of the latter possibility are reports of V. (36) and VL (37) gene mutations in CLL patients whose B cells lacked CD5 expression. Although our patients display typical features of CLL and their expanded leukemic clones express CD5, they do comprise a subset defined by the production of IgG antibodies (9) . Thus, our data are compatible with both the studies of Cai et al. and Rassenti and Kipps, providing clear evidence for somatic diversification of V region genes in a subset of leukemic CD5 + B cells that have undergone an isotype class switch. Furthermore, our studies indicate that mutations can occur in the V genes of both the H and L chains and that the numbers and locations of these changes are closely paralleled in individual patients. However, it should be noted that the extent of mutation documented in these leukemic CD5 + B cells is not as extensive as that observed in CD5 + B cells from sites of chronic inflammation (38) .
Antigen Selection. The diversification detected in this study is distributed differently among the V region genes of the various patients. In some cases (e.g., patients 001 and 033), nucleotide differences are randomly distributed, whereas in others (e.g., patient 030) these are clustered in the CDR. In contrast, patients 039, 040, and 057 demonstrate virtually no changes in their VH or V~ segments, but exhibit extensive changes in D and JH and unique changes at the VL-JL junctions. Although the H chain disparities could have arisen by V. gene replacement, the lack of mutation seen in the corresponding VL segments of these same patients suggests that this mechanism is a less likely explanation.
These somatic changes result in significant and differing numbers of replacement changes at the amino acid level. It is accepted that the presence of an R/S ratio t>3 in the CDR with lower ratios in the FR suggests antigen selection of the somatically generated substitution (39) . These criteria are met for the V. of patient 030 (K/S >7 in CDR and 0.6 in FR). In addition, the clustering of replacement substitutions in CDR2 and between amino acids 73 and 76 of FR3 of patient 055 suggest antigen selection, since this portion of FR3 of the V. is known to affect antibody binding to DNA (40, 41) and the conformation of the antigen-binding site (42) . Similarly, the VL of patient 030 has an R/S substitution ratio clearly compatible with antigen selection (CDR, 3.3; FR, 0.3), and the V~ of patient 055 has an R/S ratio and pattern similar to that in V., again with involvement of the amino acids in the CDR and FR3, at or around position 76 of the L chain.
However, the most striking indications of selection are the amino add changes that have occurred in the CDR3 of the H and L chains of patients 039 and 057. Indeed, despite the use of different germline D and J. genes, the addition of different numbers and types of nucleotides at the joints, and the difference in levels of trimming or deletion, identity at 11 of 17 amino acid positions has been achieved by somatic processes (Fig. 2 A) . In addition, a basic arginine residue has been created at the VL-JL joints in each case (Fig. 2 B) . This also is striking since these two B cells used different J~ genes and exhibited different levels of trimming and N addition at these joints. Considering that both patients' CLL cells use the same, virtually nonmutated V. (4.18) and VL (02) genes, the amino acid structure of their two antigen receptors is >95% similar. Thus, there appear to be selective pressures, presumably antigenic, to mutate the CDR3 of V, and the V-J junctions of V~ to yield remarkably similar amino acid sequences and maintain the identity of the rest of the combining sites in these two patients. Finally, since both patients' CLL cells use qr3 H chains, one must consider strongly that a similar type of antigenic drive and cellular help has been involved in their diversification and selection processes.
Implications for CLL and Its Evolution. These data demonstrate conclusively that somatic mutations of Ig V region genes can be found in certain CLL clones. However, the data do not indicate when these mutations occurred in relation to the leukemogenic event(s). If they occurred before, then our data would be consistent with the notion that transformation renders these cells/genes less "mutable." In addition, they would indicate that the transformation event need not occur in a relatively immature B cell whose V genes still have a germline-like sequence, as has been suggested recently (21) . In contrast, if these mutations are ongoing, this would suggest that these cells behave more like their normal counterparts. Our 3-yr follow-up study of the accumulation of only limited numbers of mutations between FK2 --~ JR in five patients is relevant here. However, this issue needs more extensive study in more patients. Our data also are consistent with the idea that antigenic stimulation may be involved in the clonal amplification in this disease. Studies of other lymphoid malignancies are compatible with this view (43) (44) (45) . Considering the known propensity of CD5 + CLL cells to be autoreactive (3) (4) (5) , autoantigenic drive through the B cell antigen receptor is an attractive possibility. However, surprisingly, the IgG antibodies secreted by these CD5 + CLL cells did not react significantly with a panel of six classical autoantigens (9) . This observation appears to relate at least in part to antibody valency (9) . However, in addition, the somatic mutations documented here may have sufficiently altered their binding sites away from reactivity with an original (auto)antigen in favor of another or of an exoantigen (46, 47) .
Finally, these studies suggest that our understanding of the triggering capabilities and requirements for CLL cells may be too simplistic. Somatic diversification of normal CD5-B cells appears to be initiated by antigen, require T cell help, and occur in germinal centers, whereas CD5 + B cells are considered to be triggered by T cell-independent antigens, presumably in the mantle zones of lymph nodes (for review see reference 48). However, although studies in humans support this general view (49) , others also indicate that human CD5 § B cells, both normal and leukemic, can respond to T cell-derived stimuli (50, 51) . Indeed, the preferential use by our patients' CD5 + B cells of 3'1 and 3'3 subclass genes and the absence of 3`2 (Table 1; 9) might favor the latter mechanism, since studies suggest that, in general, T cell-dependent protein antigens induce switching to IgG1 and IgG3, while switching to IgG2 frequently can be a function of T cell-independent polysaccharide antigens (for a review see reference 52). Finally, since at least in the murine system it is thought that CD5 + B cells may represent a different cellular lineage (53) that follows a distinct differentiation pathway, such cells might use different mechanisms or anatomic sites to achieve somatic diversification. Similarly, diversification might occur in a distinct subset of these cells, due either to inherent subset differences or differences in accessory cell or T cell helper function. The latter might be especially relevant since we have shown previously that most IgM-producing CLL patients have diminished T cell helper function (54) . The surface phenotypes of these IgG+CD5 + CLL B cells and their T cell functions are being evaluated to determine whether unique features exist for these particular cases.
